Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle D'Aosta Region, Italy, in the 2023-2024 Epidemic Season

Overview

Journal Vaccines (Basel)

Date 2024 May 25

PMID 38793800

Authors

Alessandra Consolati

Mariapaola Farinelli

Paolo Serravalle

Christine Rollandin

Laura Apprato

Susanna Esposito

Salvatore Bongiorno

Affiliations

Soon will be listed here.

Abstract

Respiratory syncytial virus (RSV) bronchiolitis remains a significant global health burden, particularly in newborns and infants during their first year of life. The quest for an effective preventive strategy against RSV has long been sought, and recent developments have shown promise in the form of nirsevimab, a monoclonal antibody specifically designed for RSV prophylaxis. Valle d'Aosta was the first Italian region to propose universal prophylaxis with nirsevimab for newborns and infants in their first epidemic season as early as 2023-2024. This study describes the effectiveness and safety of the universal prevention program of RSV bronchiolitis using the monoclonal antibody nirsevimab in children resident in Valle d'Aosta born during the 2023-2024 epidemic season. There were 556 neonates born from 1 May 2023 to 15 February 2024. The risk of hospitalization for RSV bronchiolitis in 2023-2024 was 3.2%, compared to 7% in the 2022-2023 epidemic season ( < 0.001). After the start of the prophylaxis campaign with nirsevimab, the risk of hospitalization was 8.3% in the sample of infants who did not adhere to the prophylaxis, while no child in the sample of those treated ( < 0.001) was hospitalized for bronchiolitis. Few mild transient side effects were reported. This study shows the efficacy and safety of universal prophylaxis with nirsevimab in neonates, making Valle d'Aosta the first Italian region to offer universal prophylaxis to newborns without risk factors for RSV complications. Future research could further explore its long-term impact and cost-effectiveness.

Citing Articles

Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus.

Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J JAMA Netw Open. 2025; 8(3):e250380.

PMID: 40063022 PMC: 11894488. DOI: 10.1001/jamanetworkopen.2025.0380.

Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection.

Manti S, Baraldi E Ital J Pediatr. 2025; 51(1):26.

PMID: 39905524 PMC: 11796128. DOI: 10.1186/s13052-025-01844-9.

Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.

Ricco M, Abu-Raya B, Icardi G, Spoulou V, Greenberg D, Pecurariu O Vaccines (Basel). 2025; 12(12.

PMID: 39771979 PMC: 11679680. DOI: 10.3390/vaccines12121317.

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France.

Ocana de Sentuary C, Testard C, Lagree M, Leroy M, Gasnier L, Enes-Dias A EClinicalMedicine. 2024; 79:102986.

PMID: 39726670 PMC: 11669793. DOI: 10.1016/j.eclinm.2024.102986.

Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization.

Shanklin A, Olson T, Patel A, Trujillo Rivera E, Pollack M JAMA Netw Open. 2024; 7(10):e2440997.

PMID: 39453655 PMC: 11581606. DOI: 10.1001/jamanetworkopen.2024.40997.

References

Moline H, Tannis A, Toepfer A, Williams J, Boom J, Englund J . Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024; 73(9):209-214. PMC: 10932582. DOI: 10.15585/mmwr.mm7309a4. View

Hak S, Venekamp R, Billard M, van Houten M, Pollard A, Heikkinen T . Substantial Burden of Nonmedically Attended RSV Infection in Healthy-Term Infants: An International Prospective Birth Cohort Study. J Infect Dis. 2024; 229(Supplement_1):S40-S50. DOI: 10.1093/infdis/jiad477. View

Kobayashi Y, Togo K, Agosti Y, McLaughlin J . Epidemiology of respiratory syncytial virus in Japan: A nationwide claims database analysis. Pediatr Int. 2021; 64(1):e14957. PMC: 9300113. DOI: 10.1111/ped.14957. View

Jefferies K, Drysdale S, Robinson H, Clutterbuck E, Blackwell L, McGinley J . Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). J Infect Dis. 2020; 222(Suppl 7):S658-S665. DOI: 10.1093/infdis/jiaa239. View

Esposito S, Abu Raya B, Baraldi E, Flanagan K, Martinon Torres F, Tsolia M . RSV Prevention in All Infants: Which Is the Most Preferable Strategy?. Front Immunol. 2022; 13:880368. PMC: 9096079. DOI: 10.3389/fimmu.2022.880368. View

Dovizio M, Veronesi C, Bartolini F, Cavaliere A, Grego S, Pagliaro R . Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy. Ital J Pediatr. 2024; 50(1):57. PMC: 10964524. DOI: 10.1186/s13052-024-01628-7. View

Wang X, Li Y, Shi T, Bont L, Chu H, Zar H . Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data. Lancet. 2024; 403(10433):1241-1253. DOI: 10.1016/S0140-6736(24)00138-7. View

Esposito S, Abu-Raya B, Bonanni P, Cahn-Sellem F, Flanagan K, Martinon Torres F . Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Front Immunol. 2021; 12:708939. PMC: 8386277. DOI: 10.3389/fimmu.2021.708939. View

Lopez-Lacort M, Munoz-Quiles C, Mira-Iglesias A, Lopez-Labrador F, Mengual-Chulia B, Fernandez-Garcia C . Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024; 29(6). PMC: 10853977. DOI: 10.2807/1560-7917.ES.2024.29.6.2400046. View

10.

Clopper B, Zhou Y, Tannis A, Staat M, Rice M, Boom J . Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019. J Pediatr. 2024; 271:114045. DOI: 10.1016/j.jpeds.2024.114045. View

11.

Muller W, Madhi S, Nunez B, Baca Cots M, Bosheva M, Dagan R . Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med. 2023; 388(16):1533-1534. DOI: 10.1056/NEJMc2214773. View

12.

Bianchini S, Silvestri E, Argentiero A, Fainardi V, Pisi G, Esposito S . Role of Respiratory Syncytial Virus in Pediatric Pneumonia. Microorganisms. 2020; 8(12). PMC: 7766387. DOI: 10.3390/microorganisms8122048. View

13.

Kopera E, Czajka H, Zapolnik P, Mazur A . New Insights on Respiratory Syncytial Virus Prevention. Vaccines (Basel). 2023; 11(12). PMC: 10747926. DOI: 10.3390/vaccines11121797. View

14.

Kato M, Mochizuki H, Kama Y, Kusuda S, Okada K, Yoshihara S . Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study. Pediatr Pulmonol. 2023; 59(3):743-749. DOI: 10.1002/ppul.26824. View

15.

. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014; 134(2):e620-38. DOI: 10.1542/peds.2014-1666. View

16.

Dagan R, Hammitt L, Nunez B, Baca Cots M, Bosheva M, Madhi S . Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season. J Pediatric Infect Dis Soc. 2024; 13(2):144-147. PMC: 10896255. DOI: 10.1093/jpids/piad113. View

17.

Li Y, Wang X, Blau D, Caballero M, Feikin D, Gill C . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399(10340):2047-2064. PMC: 7613574. DOI: 10.1016/S0140-6736(22)00478-0. View

18.

Manti S, Staiano A, Orfeo L, Midulla F, Marseglia G, Ghizzi C . UPDATE - 2022 Italian guidelines on the management of bronchiolitis in infants. Ital J Pediatr. 2023; 49(1):19. PMC: 9912214. DOI: 10.1186/s13052-022-01392-6. View

19.

Baraldi E, Bonadies L, Manzoni P . Evidence on the Link between Respiratory Syncytial Virus Infection in Early Life and Chronic Obstructive Lung Diseases. Am J Perinatol. 2020; 37(S 02):S26-S30. DOI: 10.1055/s-0040-1714345. View

20.

Levien T, Baker D . Formulary Drug Reviews: Nirsevimab. Hosp Pharm. 2024; 59(2):138-145. PMC: 10913880. DOI: 10.1177/00185787231212620. View